Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study

Huang, Szu-TingSzu-TingHuangYU-SHAN HUANGWANG-DA LIUSUNG-CHING PANHSIN-YUN SUNLien, Chia-EnChia-EnLienChen, CharlesCharlesChenSZU-MIN HSIEH2023-09-072023-09-072023-06-1409296646https://scholars.lib.ntu.edu.tw/handle/123456789/635196MVC-COV1901 is a protein vaccine based on the same SARS-CoV-2 strain used in mRNA vaccine mRNA-1273. Data are lacking on immunogenicity and safety of MVC-COV1901 as heterologous boost for people already received one dose of mRNA-1273.enCOVID-19; Heterologous prime boost; Immunogenicity; Protein-based vaccine; mRNA vaccine[SDGs]SDG3Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled studyjournal article10.1016/j.jfma.2023.05.030373219552-s2.0-85162173579https://api.elsevier.com/content/abstract/scopus_id/85162173579